Table 1.
Patients characteristics at baseline
| All (n=880) |
Subtype B (n=681) |
Non-B subtypes (n=199) |
|
|---|---|---|---|
| Age, years, median (IQR) | 42.7 (41.6-44.6) | 42.6 (41.5-44.6) | 43.4 (42.1-44.7) |
| Male gender, n (%) | 688 (78.2) | 583 (85.6) | 105 (52.8) |
| HIV RNA log10 copies/mL, median (IQR) | 4.3 (3.3-4.9) | 4.4 (3.5-4.9) | 3.9 (3.1-4.8) |
| CD4 counts cells/mm3, median (IQR) | 215 (96-363) | 220 (98-370) | 197 (90-330) |
| Median nr of previously used ARV drugs (IQR) | 9 (4-13) | 10 (4-13) | 7 (3-11) |
| Median nr of previously used NRTI (IQR) | 5 (2-6) | 5 (3-6) | 4 (2-6) |
| Median nr of previously used NNRTI (IQR) | 1 (0-2) | 1 (0-2) | 1 (0-1) |
| Median nr of previously used PI (IQR) | 3 (1-5) | 3 (1-5) | 2 (1-4) |
| Previous lopinavir use, % | 70.1 | 70.2 | 69.8 |
| Previous tipranavir use, % | 25.3 | 26.7 | 20.6 |
| Previous etravirine, % | 8.8 | 9.1 | 7.5 |
| Previous enfuvirtide use, % | 27.3 | 29.4 | 20.1 |
| Previous raltegravir use, % | 10.0 | 10.0 | 10.1 |
| Previous maraviroc use, % | 8.1 | 7.9 | 8.5 |
Abbreviations: ARV, antiretroviral; IQR, interquartile range; Nr, number; NRTI: nucleos(t)ide reverse transcriptase inhibitor; non-NRTI, NNRTI; PI, protease inhibitor.